4basebio Statistics

Total Valuation

4basebio has a market cap or net worth of GBP 166.47 million. The enterprise value is 179.24 million.

Market Cap	166.47M
Enterprise Value	179.24M

Important Dates

The next estimated earnings date is Friday, December 27, 2024.

Earnings Date	Dec 27, 2024
Ex-Dividend Date	n/a

Share Statistics

4basebio has 12.81 million shares outstanding. The number of shares has increased by 1.59% in one year.

Current Share Class	n/a
Shares Outstanding	12.81M
Shares Change (YoY)	+1.59%
Shares Change (QoQ)	+3.16%
Owned by Insiders (%)	16.40%
Owned by Institutions (%)	34.60%
Float	2.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	272.97
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-18.22
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-19.95

Financial Position

The company has a current ratio of 2.73

Current Ratio	2.73
Quick Ratio	1.53
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-1.72
Interest Coverage	-18.65

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-54.30%
Return on Capital (ROIC)	-62.02%
Revenue Per Employee	5,901
Profits Per Employee	-97,406
Employee Count	84
Asset Turnover	0.05
Inventory Turnover	0.65

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +145.28% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+145.28%
50-Day Moving Average	1,341.90
200-Day Moving Average	1,268.33
Relative Strength Index (RSI)	45.34
Average Volume (20 Days)	25,991

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, 4basebio had revenue of GBP 596,000 and -9.84 million in losses. Loss per share was -0.79.

Revenue	596,000
Gross Profit	415,000
Operating Income	-10.20M
Pretax Income	-10.63M
Net Income	-9.84M
EBITDA	-9.63M
EBIT	-10.20M
Loss Per Share	-0.79

Full Income Statement

Balance Sheet

The company has 2.72 million in cash and 15.49 million in debt, giving a net cash position of -12.78 million or -1.00 per share.

Cash & Cash Equivalents	2.72M
Total Debt	15.49M
Net Cash	-12.78M
Net Cash Per Share	-1.00
Equity (Book Value)	-5.22M
Book Value Per Share	-0.41
Working Capital	3.12M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -8.33 million and capital expenditures -653,000, giving a free cash flow of -8.99 million.

Operating Cash Flow	-8.33M
Capital Expenditures	-653,000
Free Cash Flow	-8.99M
FCF Per Share	-0.70

Full Cash Flow Statement

Margins

Gross Margin	69.63%
Operating Margin	-1,711.58%
Pretax Margin	-1,784.23%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-1,507.55%

Dividends & Yields

4basebio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.59%
Shareholder Yield	-1.59%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

4basebio has an Altman Z-Score of -2.69. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.69
Piotroski F-Score	n/a